Optherion, a New Haven, CT-based developer of diagnostics an drugs for eye and kidney diseases, has raised $5 million in a planned $9.5 million convertible notes and warrants offering, according to an SEC filing. The company writes in the filing that the notes and warrants can be converted into capital stock under certain conditions. Colin Foster, president and CEO of Optherion, was not immediately available for comment this morning. Optherion turned heads when it announced a $37 million Series A round of financing in October 2007 to develop a treatment for age-related macular degeneration.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
